* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周三早盘涨幅扩大至5.9%。
* 该公司此前公告称，自主研发的伊匹木单抗生物类似药HLX13一线治疗不可切除的肝细胞癌患者的国际多中心1期临床研究于中国境内完成首例患者给药。
* 复宏汉霖今年迄今暴涨196%，同期恒生指数.HSI上扬30.1%。
* 恒⽣⽣物科技指数.HSBIO盘中升3%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 张喜良)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.